Upload Records Snowball Search Search OpenAlex
About the database ScholarIQanswers from OpenAlex
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial
PaperCitations, authors & open-access status
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial is a paper indexed in ScholarIQ from OpenAlex. ScholarIQ records 719 citations, 2022 year and hybrid oa status.
719
Citations
2022
Year
hybrid
OA Status